Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620074 | 0.89 | POLB (0.66) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL23146038 | 0.85 | HPGD (0.53) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL95372 | 0.82 | KDM4E (0.60) | POLBALDH1A1KDM4ELMNAKMT2A | |
| SCHEMBL23671122 | 0.82 | MAOB (0.68) | POLBALDH1A1KDM4ESPHK2MAPK1 | |
| SCHEMBL23471096 | 0.82 | POLB (0.58) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL8142775 | 0.82 | POLB (0.58) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL24386099 | 0.80 | POLB (0.56) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL12893201 | 0.80 | MMP13 (0.60) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL1665183 | 0.80 | OGG1 (0.59) | POLBHPGDHTTMMP13CA12 | |
| SCHEMBL853629 | 0.80 | KDM4E (0.61) | POLBHPGDHTTMMP13CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | claimed |
| CN-114727983-A | Xanthine CB1 inhibitors | 金翅雀生物公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021062089-A1 | XANTHINE CB1 INHIBITORS | GOLDFINCH BIO, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7834037-B2 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | AMIRA PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | POLB 1340/4885HPGD 2146/4885HTT 4495/4885 |
| US-20090018170-A1 | 1,3,5-Substituted indole derivatives, e.g., 3-[3-tert-butylthio-1-[4-(6-methoxypyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-indol-2-yl]-2,2-dimethyl-propionic acid; used alone and in combination with other compounds for treating leukotriene-dependent diseases such as respiratory and cardiovascular | LTC4S, ALOX5, LTA4H | POLB 2738/4885HPGD 83/4885HTT 4120/4885 |
| US-20110034514-A1 | 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors | ALOX5, ALOX15B, ALOX15 | POLB 1953/4885HPGD 81/4885HTT 4772/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | POLB 4329/4885HPGD 2322/4885HTT 4175/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | POLB 4329/4885HPGD 2322/4885HTT 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.